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1. Introduction 
Pancreatic ascites or internal pancreatic fistulae and pancreatic pleural effusion are rare 
complications of pancreatitis. This can occur in the clinical setting of an acute pancreatitis 
and more commonly as a complication of chronic pancreatitis1. This is an uncommon 
clinical condition; often the patients are sick and nutritionally compromised. Pancreatic 
ascites was first reported in the literature in 1953 when Smith described two cases of ascites 
associated with chronic pancreatitis2.  
2. Definition  
Exact definition to diagnose this condition is not clear in the literature. Pancreatic ascites 
/pleural effusion is characterised by accumulation of high amylase fluid in the peritoneal 
cavity/pleural cavity due to leakage of pancreatic juice from a disrupted pancreatic duct 
and a diagnosis is usually made once the aspirated fluid is high in protein (>3g/dl) and high 
in amylase (>1000 IU/L)3.   
3. Aetiology and pathogenesis  
Pancreatic ascites/pleural effusion can occur due to a) rupture of a pseudocyst into 
peritoneal cavity or to mediastinum and pleura or b) due to the disruption of a main 
pancreatic duct during the natural course of chronic pancreatitis3. Pancreatic leak occurs in 
3.5% of patients with chronic pancreatitis and 6% to 14% of patients with pancreatic 
pseudocyst 4, 5. The pathogenesis of the serous cavity effusion is different in acute and 
chronic pancreatitis setting. In acute pancreatitis, mostly in alcoholic pancreatitis, there is 
enough inflammatory reaction around the pancreas with neighbouring structures like 
stomach and transverse colon to form a pseudocyst. This can rupture into peritoneal cavity 
or mediastinum and to pleural cavity subsequently to produce ascites or pleural effusion 
respectively. Similar type of duct disruptions may also occur in acute setting in blunt 
abdominal trauma, biliary pancreatitis, and rupture of duplication cyst and rarely after 
pancreatic surgery or splenectomy1, 6.  
In the setting of chronic pancreatitis, leakage is seen in up to 80% of cases from a 
communicating pseudocyst due to ductal stricture and less commonly (20%) due to duct 
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disruption itself3, 7. This has also been described in the setting of tropical calcific pancreatitis 
as well from duct disruptions and leaking pseudocyst8. Once the amylase rich fluid enters 
serous cavity, since the enzymes are not activated it does not produce digestion, instead it 
produces irritation resulting in outpouring of albumin resulting in high-albumin ascites. 
This accumulation of amylase rich fluid is usually massive before it produces symptoms due 
to its pressure effects. The amylase in the fluid can get reabsorbed into the blood stream and 
produce elevation of serum amylase as well. It has been also reported in one series that 
pancreatic ascites or effusions may present with indolent symptoms and up to 42% of 
patients gave no history of pancreatic disease9. 
4. Diagnosis and evaluation  
Aim of the investigations in patients with pancreatic ascites are a). Overall assessment of 
patient’s general and nutritional status and b). To delineate the pancreatic ductal anatomy 
and to locate the possible site of leak. These patients should have a haemogram, serum 
protein, and albumin and amylase value and coagulation profile. Upper GI endoscopy to 
rule out peptic ulcer or periampullary malignant disease and ultrasonography should be 
done. The diagnosis is usually confirmed with ascitic fluid assay. Usually the ascitic/pleural 
fluid contains high protein >3g/dl and high amylase >1000 IU/ml. Ascitic fluid assay 
should also be done to rule out other differential diagnosis like cirrhosis of liver or 
disseminated malignancy.  
The localization of site of rupture or leak of main pancreatic duct is essential for planning 
therapy. Earlier, intraoperative pancreatography was the mainstay of localisation which is 
superseded largely by Endoscopic Retrograde Pancreatography (ERP) in recent years. 
However, these procedures are invasive and correct delineation of the duct anatomy and 
leak may not be feasible in all cases due to strictures or due to technical reasons. 
Demonstration of pancreatic duct leak by non invasive methods offer advantages like 
avoiding a sedation or anaesthesia, avoiding risk of introducing infection during injection 
of dye to the pancreatic duct. Non invasive investigations like CT scan helps in 
indentifying peripancreatic collections and details of the parenchyma of the pancreas. The 
details of pancreatic parenchyma, duct size, stones, strictures and psuedocysts are well 
displayed in a CT scan. The identification of site of leak from the pancreatic duct is 
possible in nearly half of the patients10. Magnetic Resonance Imaging (MRI) has also been 
reported to give good details of pancreatic parenchyma, details of the duct and details of 
the fistula11, 12. In MRP, high signal intensity of static or slowly flowing liquids is observed 
in T2 weighted images. Hence the pancreatic duct and the fistulous tract is displayed as 
high-signal intensity structure which helps in identifying the communication like 
pancreaticopleural fistula. The details of the pancreatic parenchyma and duct structural 
changes are also well displayed in MRI. Moreover, in MRI no contrast material is injected 
and there is no risk of infection in comparison with ERP. In a recent study13, the ability of 
helical CT scan and Magnetic Resonance Pancreatography (MRP) when performed alone 
in identifying the site of duct disruption were 50 and 67% respectively. When these two 
modalities were combined the exact site of rupture of duct was observed in 94% of cases. 
Hence, a combination of imaging modalities helps to improve the details of the duct 
disruption,the site of leak and the details of the pancreatic parenchyma which is essential 
in planning of therapy.  
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5. Management 
Management of these patients are challenging due to the compromised nutritional state, 
generalized weakness, diabetes mellitus and disease related factors like multiple strictures, 
large stones and inflammatory mass. All patients with a diagnosis of pancreatic ascites or 
pleural effusion should be assessed for their nutritional status. This is important as the 
morbidity and mortality of the various modes of treatment is related to the patient’s general 
condition. These patients may be managed by conservative approach, endoscopic therapy 
and by surgical therapy. This may be done in using an algorithm depending upon patient’s 
clinical condition8. (Table 1)  
Algorithmic approach to the management of Pancreatic ascites
Pancreatic Ascites
Assessment
CT scan ± MRI
ERCP
Control of ascites, pain
Poor nutrition
Nasojejunal feeds
Aspiration, Octreotide
Follow up
Failed 
Cannulation / stenting
Persistent
ascites, pain
Surgery
Pancreatic stenting
 
Table 1. Algorithmic approach to the management of pancreatic ascites. 
6. Conservative treatment 
Initial trial of conservative treatment is indicated in almost all patients. It was generally 
believed that there is high risk for mortality while the patients are on conservative therapy, 
which is due to poor nutritional management and assessment in the initial reports. Though 
an old series14 had reported high mortality with conservative therapy, the progress of the 
patient can be safely monitored on conservative therapy in current daily practice. The key 
steps in the conservative management of the pancreatic ascites or pleural effusion are a). 
Rest to the pancreas and to limit pancreatic exocrine stimulation by keeping the patients nil 
orally, b). Nutritional support by means of nasojejunal feeds or by Total Parenteral Nutrition 
(TPN), c). Use of drugs likes to decrease pancreatic secretion d). Drainage of fluid by 
aspiration, drainage of ascites or by tube thoracocentesis. So patients are kept nil per oral 
and nutritional support should be planned on case to case basis. There is no significant 
difference between enteral or parenteral feeds on pancreatic exocrine secretion clinically15. 
However, these patients are often nutritionally compromised and have nausea, anorexia and 
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poor tolerance to feeds due to exocrine insufficiency. Enteral nutritional support should be 
attempted whenever possible as it maintains mucosal integrity and prevents bacterial 
translocation. Nasojejunal feeds have a theoretic benefit as it prevents stimulation of 
pancreas and minimises fistula output. In patients who do not tolerate enteral feeds well or 
those with catabolic response TPN should be used either alone or along with enteral feeds.  
Serous cavities should be emptied to promote approximation of serosal surfaces by drainage 
of ascitic/pleural fluid. Repeated aspiration of ascites or drainage of the ascites with the 
tube near the pseudocyst helps to drain the fluid by a controlled fistula. Similarly, aspiration 
or tube drainage should be done according to be patient’s symptoms. Along with above 
measures, use of drugs with the aim to decrease the pancreatic exocrine secretion like 
somatostatin or octreotide also have a role in improving the pancreatic leak15-17. These drugs 
have been noted to decrease the fistula output (often within 24 hours of treatment) and 
accelerate the fistula closure. Depending upon the clinical situation a conservative therapy 
with above measures for 3-4 weeks helps in resolution of pancreatic leak in 25 – 60% of 
cases17,18. Patients with low sodium levels, albumin levels and those with a high fluid to 
serum protein levels had high chance for treatment failure18. Other agents attempted in 
closure of pancreatic leak are fibrin glue and nafamostat mesilate with variable results. 
Patients those who fails to respond to conservative measures or those patients who are 
symptomatic should undergo endotherapy or surgery.  
7. Endotherapy 
Endoscopic Retrograde Pancreatography (ERP) is the key step in planning of endoscopic 
treatment. ERP helps to delineate the anatomy of the duct, presence of strictures and site 
pancreatic leak (Figure 1). The principles of endotherapy include pancreatic sphincterotomy 
and placement of a transduodenal pancreatic stent across the site of ductal leak. This helps 
to obliterate the high-pressure gradient at the pancreatic sphincter, allowing preferential 
flow of pancreatic secretions along a low resistance path to the duodenum, thereby allowing 
the site of leak to heal. This has been reported in many series6, 8,13,19,20. It has been observed 
that a sphincterotomy and placement of stent close to the fistula, even if the stent could not 
be advance beyond the site of leak helps to heal the fistula or stabilizes patients clinical 
condition8. Other endoscopic approaches which are practised are endoscopic placement of 
nasopancreatic drainage21 and endosonography guided pancreatogastrostomy22. 
Nasopancreatic drainage alone has been used instead of placement of pancreatic duct 
stenting in treatment of pancreatic ascites22. The authors have reported nearly 90% of 
success in placement of nasopancreatic drain and disappearance of pseudocyst and ascites 
were observed on 4-6 weeks. Nasopancreatic drains allow repeated pancreatography to 
assess the progress of therapy and healing of the duct. This method provides the option of 
flushing of the drain to clear the blocks and allows removal of the drain once the duct 
disruption is healed. The disadvantages of this method are the discomfort to the patients 
due to the nasal tube and risk of accidental dislodgement.  
The success of endotherapy ranges from 50-90% depending upon the duct changes8, 19-21. 
Success of endoscopic treatment was based on three factors in this study a) ability to pass 
the stent across the site of disruption of the duct, b) absence of strictures and stones and c) 
ability to traverse the stricture. Those patients who had only partial relief of symptoms and 
those with failed endotherapy would require surgery.  
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Fig. 1. Endoscopic retrograde pancreatography showing leak of dye from tail duct. 
8. Surgery 
The surgical intervention is planned according to the ductal anatomy and site of leak (figure 
2). Aims of the surgery in patients with chronic pancreatitis with pancreatic ascites are to a) 
wide drainage of pancreatic duct, often with a Lateral Pancreatojejunostomy (LPJ) b) 
removal of pancreatic stones and ductal strictures and c) drainage of the cysts and external 
drainage of abscess. 
Patients with chronic pancreatitis with large duct (>7mm) should undergo wide drainage of 
pancreatic duct often with a lateral panctreatojejunostomy and removal of pancreatic stones 
and ductal strictures5, 7, 8. Specific repair of the site or disruption is often unnecessary; 
however the area of disruption should be included in the anastomosis. Similarly, a mature 
pseudocyst also can be incorporated in the anastomosis. In patients with normal sized duct, 
identification of the site of leak is very important. In those with distal leak, a distal 
pancreatectomy with or without splenectomy is a good option. Spleen preservation is often 
difficult in these patients due to dense adhesions and inflammatory process. If the 
inflammation and fibrosis is significant a medial to lateral approach in distal 
pancreatectomy may be used to avoid excessive bleeding.  
www.intechopen.com
 
Pancreatitis – Treatment and Complications 
 
200 
 
Fig. 2.  Operative picture showing disruption of pancreatic duct in the body region with 
pancreatic stent in situ coming out through the site of disruption.  
In those with leak from the neck region Roux –en-Y anastomosis to the fistula site or 
pancreatogastrostomy has been described. In those patients with disconnected duct  
syndrome, often secondary to acute pancreatic necrosis, there is often a loss of tissue near 
the genu with fistula from either distal or proximal duct. A Roux-en-Y anastomosis to the 
distal duct and closure of the proximal duct or distal pancreatectomy with closure of 
proximal duct may be performed according to the clinical situation. In patients with long 
fistulous tract to skin, dissection of fistula and fistula-enterostomy has been reported with 
varying results23. Surgery for pancreatic ascites is often difficult due to the dense 
inflammatory process in the peripancreatic tissue, mesentery and due to the presence of 
pseudocysts and often identification of site of leak is difficult and cystojejunostomy to the 
leaking cyst is also an effective option24, 25. 
9. Conclusion 
Pancreatic ascites or pleural effusion are rare complications of acute or chronic pancreatitis 
wherein there is leakage of pancreatic juice to a serous cavity from a disrupted pancreatic 
duct or leaking pseudocyst. Preoperative workup should be aimed at the nutritional 
assessment of the patient and the pancreatic ductal imaging using CT scan or MRI. An 
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algorithmic approach may be adopted in managing this patients using conservative, 
endotherapy or surgical treatment according to the clinical scenario. A multidisciplinary 
approach of these modalities is essential for successful management of these patients. 
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